Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer

Background: S-1, a novel oral fluoropyrimidine, is well tolerated in patients with metastatic colorectal cancer (mCRC). The response rate of S-1 for colorectal cancer is high, ranging from 35% to 40%. This study aimed to evaluate the safety and efficacy of S-1 combined with oral leucovorin (LV) to e...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Koizumi, W., Boku, N., Yamaguchi, K., Miyata, Y., Sawaki, A., Kato, T., Toh, Y., Hyodo, I., Nishina, T., Furuhata, T., Miyashita, K., Okada, Y.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2010
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2844944/
https://ncbi.nlm.nih.gov/pubmed/19828562
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdp371
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados